2022

1. Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry

   European Journal of Clinical Investigation, Vol. 52, Núm. 12

2. Sex Differences in Low-Density Lipoprotein Cholesterol Reduction with PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry

   Journal of Cardiovascular Pharmacology, Vol. 79, Núm. 4, pp. 523-529